Sharp, practical thinking on building, funding and transacting healthcare ventures, projects and M&A across the region — published by our team on LinkedIn.
What separates a profitable specialty practice from a scalable, investable business? As founder-led clinics approach succession and private capital moves across ASEAN, the gap is rarely one of clinical quality — it's one of structure. Four tests of scalability, and how founder-dependence can be removed function by function.
Read on LinkedIn
The installed cyclotron count in Southeast Asia overstates the commercially viable asset base. GMP certification, distribution geography, commercial architecture and specialty isotope capability are the four constraints that separate hardware from investable infrastructure — and the gap between the two figures is the investment thesis.
Read on LinkedIn
Over the past three years, pharmaceutical companies have committed roughly US$10 billion in acquisitions aimed at a single therapeutic category: radiopharmaceuticals — and the world's fastest-growing nuclear medicine market is right here in Asia-Pacific. What the full delivery stack requires, where the region stands today, and why the centres with cyclotrons are positioned to participate in what comes next.
Read on LinkedIn
Oncology is one of the hardest businesses in healthcare to model — two patients with the same cancer can carry completely different cost profiles, driven by treatment phase, drug choice and real-world utilisation. Most models fail not for lack of data, but because they aren't decision-useful. How to translate clinical complexity into financial clarity for ASEAN operators and investors.
Read on LinkedIn
Healthcare demand across Southeast Asia is rising fast, but access to specialist care remains uneven. As countries build their own specialist capabilities, new opportunities are emerging for regional collaboration between providers, hospital groups and experienced specialists. How regional care ecosystems may develop — and what that means for specialist clinics looking beyond their domestic market.
Read on LinkedIn
Expanding into ASEAN often reveals complexities that aren't obvious from Singapore. A short reflection on the realities healthcare specialists and clinics encounter when operating across the region's markets.
Read on LinkedIn
Radiopharma in ASEAN is heating up — cancer cases rising, PET/CT access uneven, cyclotron projects accelerating. But this is not an equipment race; it's an infrastructure play. Success depends on integrated teams, GMP discipline and delivering first dose on time. The hard truths, and what it takes to build bankable, inspection-ready capacity.
Read on LinkedIn
The discipline that steers billion-dollar airports and power plants can — and should — guide hospitals, clinics and diagnostic networks in mastering cost, capacity and cash flow. Plus a look ahead: how our sister company SKYIQ's generative-AI tooling turns a static model into a conversational decision engine.
Read on LinkedInFollow KPA for our latest thinking on ASEAN healthcare ventures, projects and capital.